Core Viewpoint - The company, Jinfang Pharmaceutical-B (02595.HK), announced a global offering of 89.24 million H-shares at a price of HKD 20.39 per share, with a net proceeds of HKD 1.67 billion [1] Summary by Categories Offering Details - The global offering consists of 89.24 million H-shares, priced at HKD 20.39 each, resulting in net proceeds of HKD 1.67 billion [1] - The Hong Kong public offering accounts for 8.7% of the total shares offered, with a subscription rate of 2,662.79 times [1] - The international offering represents 91.3% of the total shares, with a subscription rate of 39.05 times [1] Trading Information - If the global offering becomes unconditional by September 19, 2025, trading of the H-shares is expected to commence on the Hong Kong Stock Exchange at 9:00 AM [1] - Each board lot for trading H-shares consists of 200 shares, with the stock code being 2595 [1]
劲方医药-B香港IPO发行价定为每股20.39港元 净筹16.7亿港元